Artgen

Artgen is a Russian biotechnology company. It was founded in 2003. It is engaged in scientific research, development of innovative drugs and high-tech services in the field of regenerative medicine, medical genetics, gene therapy, bioinsurance and biopharmaceuticals. It independently promotes his own developments in the market.
Artgen stock price chart
+4%
P/E
Net profit
P/B
Book value
Debts
Net debt
Yield
Growth potential

Artgen balance sheet

Report period2018 2019 2020 2021 2022 Q3 23
End date of the reporting period
Capitalization, ₽
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Artgen cash flows

Report period2017 2018 2019 2020 2021 2022
End date of the reporting period
Sales
Operation Income
Earnings
Shareholders earnings
EBITDA
OIBDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Artgen multipliers

Report period2018 2019 2020 2021 2022 Q3 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
Net Debt/OIBDA
EV/EBITDA
EV/OIBDA

Artgen profitability

Report period2018 2019 2020 2021 2022 Q3 23 TTM
ROA
ROE
ROS
EBITDA Margin
Operating margin
Artgen assets
Artgen cash flows
Artgen dividends
0.91%

Artgen dividend policy

The recommended amount of dividend payments is determined based on year-end financial results, economic situation, and industry position and may range from 40% to 60% of net profit.

Artgen shares

TickerNameTypeNominal valueISINPrice
ABIO:RMArtgenCommon shareRUB 0.1RU000A0JNAB6RUB 104

Artgen bonds

NameIssue sizePriceYield
ISKJ BO-01 (RUB)---
ISKJ BO-01 (RUB)300,000 pcs.92.29%12.88%
Share capital structure of Artgen
Artgen news
12.02.2024
Razvitie BioTechnologii, a member of the Artgen Group, conducted preclinical studies of the effect on the immune system of the new immunomodulator Betusfera when administered intramuscularly and systemically. Drug has proven its ability to enhance immune system activity to fight acute viral infections and increase macrophage activity, which is important for...
Source: {source} pictogram artgen.ru
23.01.2024
Artgen Biotech Group expects to increase its revenue to at least ₽10 billion by 2030. Multiple revenue growth will ensure both the launch of new drugs and the expansion of indications for existing drugs. In 9M 2023, the company reported revenue of ₽963.98 million, up 17.9% from ₽817.89 million a year earlier. In 2022, revenue fell 3.7% to ₽1.137 billion comp...
18.01.2024
Artgen Biotech's EBITDA for 9 months of 2023 amounted to ₽209.72 million, up 67.7% from ₽125.02 million in the previous year. Revenue increased 17.9% to ₽963.98 million against ₽817.89 million a year earlier.
Source: {source} pictogram artgen.ru
15.01.2024
Histograft, part of Artgen Biotech, has started clinical trials of gene-activated osteoplastic material for the treatment of patients with degenerative-dystrophic spine diseases. Material is already approved for clinical use in trauma practice, but to date no clinical data have been accumulated for large-scale introduction of the product into this segment of...
Source: {source} pictogram t.me
General information
Company nameArtgen
Tags#biotechnology, #pharmacy, #innovations of the russia
SectorHealth Care / Health Care Equipment & Services / Health Care Providers & Services / Health Care Services
Business addressRF, g. Moskva
Mailing address117036, g. Moskva, prospekt 60-letiya Oktyabrya, d. 10A, etazh 3, pom. 24
CEOMasyuk Sergey Vladimirovich
Phone+7 (495) 646-80-76
Websiteartgen.ru
Information disclosuree-disclosure.ru